人工智慧合作研究与授权协议（2019-2025）

本报告分析了全球生物製药产业，并提供了2019年至2025年间959项人工智慧合作研究与授权协议的详细数据。

目录

摘要整理

第一章：引言

第二章：人工智慧合约趋势

• 引言
• 过去几年人工智慧合约
• 最活跃的人工智慧承包商
• 依合约类型划分的人工智慧合约
• 依治疗领域划分的人工智慧合约
• 依行业划分的人工智慧合约
• 人工智慧合约条款与条件
  • 人工智慧合约总价值
  • 人工智慧预付款合约
  • 人工智慧合约里程碑付款
  • 人工智慧特许权使用费率

第三章：关键人工智慧合约

• 引言
• 依价值排名的顶级人工智慧合约

第四章：最活跃的人工智慧合约公司

• 引言
• 最活跃的人工智慧合约公司
• 最活跃的人工智慧合约公司简介

第五章：人工智慧合约名录

• 引言
• 人工智慧合约名录

第六章：依技术类型划分的人工智慧合约

• 合约名录
• 合约名录 - 人工智慧合约：依公司（A-Z）
• 合约名录 - 人工智慧合约：依合约类型
• 合约目录 - AI 合约：依治疗领域
• 合约类型定义
• 关于 Biopharma Research Ltd
• 当前合作
• 当前协议
• 近期目前合作报告标题

Artificial Intelligence (AI) Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the artificial intelligence deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of artificial intelligence deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter artificial intelligence deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 959 artificial intelligence deals announced since 2019 including financial terms where available including links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of artificial intelligence dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in artificial intelligence dealmaking since 2019.

Chapter 3 provides an overview of the leading artificial intelligence deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in artificial intelligence dealmaking with a brief summary followed by a comprehensive listing of artificial intelligence deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of artificial intelligence deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan 2019. The chapter is organized by specific artificial intelligence technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in artificial intelligence deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Artificial Intelligence (AI) Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse artificial intelligence collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Artificial Intelligence (AI) Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of artificial intelligence trends and structure of deals entered into by leading biopharma companies worldwide.

Artificial Intelligence (AI) Collaboration and Licensing Deals includes:

• Trends in artificial intelligence dealmaking in the biopharma industry
• Directory of artificial intelligence deal records covering pharmaceutical and biotechnology
• The leading artificial intelligence deals by value
• Most active artificial intelligence licensing dealmakers
• Artificial Intelligence (AI) Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in artificial intelligence dealmaking

• 2.1. Introduction
• 2.2. Artificial intelligence deals over the years
• 2.3. Most active artificial intelligence dealmakers
• 2.4. Artificial intelligence deals by deal type
• 2.5. Artificial intelligence deals by therapy area
• 2.6. Artificial intelligence deals by industry sector
• 2.7. Deal terms for artificial intelligence deals
  • 2.7.1 Artificial intelligence deals headline values
  • 2.7.2 Artificial intelligence deal upfront payments
  • 2.7.3 Artificial intelligence deal milestone payments
  • 2.7.4 Artificial intelligence royalty rates

Chapter 3 - Leading artificial intelligence deals

• 3.1. Introduction
• 3.2. Top artificial intelligence deals by value

Chapter 4 - Most active artificial intelligence dealmakers

• 4.1. Introduction
• 4.2. Most active artificial intelligence dealmakers
• 4.3. Most active artificial intelligence deals company profiles

Chapter 5 - Artificial intelligence contracts dealmaking directory

• 5.1. Introduction
• 5.2. Artificial intelligence contracts dealmaking directory

Chapter 6 - Artificial intelligence dealmaking by technology type

• Deal directory
• Deal directory - Artificial intelligence deals by company A-Z
• Deal directory - Artificial intelligence deals by deal type
• Deal directory - Artificial intelligence deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Artificial intelligence deals since 2019
• Figure 2: Active artificial intelligence dealmaking activity - 2019 - 2025
• Figure 3: Artificial intelligence deals by deal type since 2019
• Figure 4: Artificial intelligence deals by therapy area since 2019
• Figure 5: Artificial intelligence deals by industry sector since 2019
• Figure 6: Artificial intelligence deals with a headline value
• Figure 7: Artificial intelligence deals with an upfront value
• Figure 8: Artificial intelligence deals with a milestone value
• Figure 9: Artificial intelligence deals with a royalty rate value
• Figure 10: Top artificial intelligence deals by value since 2019
• Figure 11: Most active artificial intelligence dealmakers 2019 - 2025
• Figure 12: Artificial intelligence deals by technology type since 2019